Brand Name | Status | Last Update |
---|---|---|
amlodipine and valsartan | ANDA | 2025-02-24 |
amlodipine besylate and valsartan | ANDA | 2014-12-16 |
amlodipine, valsartan and hydrochlorothiazide | ANDA | 2024-05-17 |
amlodipine, valsartan, hydrochlorothiazide | ANDA | 2025-06-02 |
amlodipine,valsartan and hydrochlorothiazide | ANDA | 2025-01-09 |
clopidogrel | ANDA | 2021-10-12 |
diovan | New Drug Application | 2025-07-21 |
diovan hct | New Drug Application | 2024-12-20 |
entresto | New Drug Application | 2025-08-12 |
exforge | New Drug Application | 2025-04-02 |
Expiration | Code | ||
---|---|---|---|
VALSARTAN, DIOVAN, NOVARTIS | |||
2024-04-19 | NPP | ||
SACUBITRIL / VALSARTAN, ENTRESTO, NOVARTIS PHARMS CORP | |||
2024-02-16 | M-82 | ||
2023-04-01 | PED |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Sacubitril / Valsartan, Entresto, Novartis Pharms Corp | |||
11058667 | 2036-05-09 | U-3170 | |
9517226 | 2033-08-22 | U-3084 | |
9937143 | 2033-08-22 | U-3084 | |
11135192 | 2033-08-22 | U-3084 | |
8877938 | 2027-05-27 | DS, DP | |
9388134 | 2026-11-08 | U-1723 | |
8101659 | 2025-01-15 | DP | |
7468390 | 2023-11-27 | DP | |
8404744 | 2023-01-14 | DP | |
8796331 | 2023-01-14 | U-1723 | |
Nebivolol Hydrochloride / Valsartan, Byvalson, Abbvie | |||
7838552 | 2027-10-04 | U-185 | |
7803838 | 2026-08-29 | DP | |
Aliskiren Hemifumarate / Valsartan, Valturna, Novartis | |||
8168616 | 2026-07-03 | DP | |
Amlodipine Besylate / Hydrochlorothiazide / Valsartan, Exforge Hct, Novartis | |||
8101599 | 2023-05-16 | DP | |
8475839 | 2023-05-16 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 2 | 13 | 61 | 47 | 3 | 125 |
Heart failure | D006333 | EFO_0003144 | I50 | — | 8 | 13 | 15 | 13 | 48 |
Essential hypertension | D000075222 | — | I10 | — | 5 | 12 | 3 | 1 | 20 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | 6 | — | 8 |
Systolic murmurs | D054160 | — | R01.1 | — | 1 | 1 | 3 | 1 | 6 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | 1 | 4 | — | 6 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | 1 | 3 | — | 5 |
Syndrome | D013577 | — | — | 1 | 1 | 1 | 2 | — | 5 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | 4 | — | 4 |
Hypertrophy | D006984 | EFO_0002460 | — | — | 1 | 1 | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | — | — | — | — | 3 | — | — | 3 |
Renal insufficiency | D051437 | — | N19 | 1 | 1 | 1 | — | — | 3 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 2 | — | — | 2 |
Infarction | D007238 | EFO_0009463 | — | — | — | 2 | — | — | 2 |
Chronic renal insufficiency | D051436 | — | N18 | 1 | — | 1 | — | — | 2 |
Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | — | 1 |
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | — | 4 |
Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 1 | — | — | — | 1 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 1 | — | — | — | 1 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | — | — | 1 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Male breast neoplasms | D018567 | — | — | — | 1 | — | — | — | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 1 | — | — | — | — | 1 |
Nephrosis | D009401 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
Microvascular angina | D017566 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Valsartan |
INN | valsartan |
Description | Valsartan is a monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, a xenobiotic and an environmental contaminant. It is a biphenylyltetrazole, a monocarboxylic acid amide and a monocarboxylic acid. |
Classification | Small molecule |
Drug class | angiotensin II receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C |
PDB | — |
CAS-ID | 137862-53-4 |
RxCUI | — |
ChEMBL ID | CHEMBL1069 |
ChEBI ID | 9927 |
PubChem CID | 60846 |
DrugBank | DB00177 |
UNII ID | 80M03YXJ7I (ChemIDplus, GSRS) |